QNCX Quince Therapeutics, Inc.: institutional ownership and insider trading
Over the last 12 months insiders bought $0 and sold $174K on the open market.
QNCX revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$75.5M, EPS -12.31
- Quarter ended Mar 31, 2026: revenue n/a, net income $35.9M, EPS 2.88
- Quarter ended Dec 31, 2025: revenue n/a, net income −$39.5M, EPS 70.74
- Quarter ended Sep 30, 2025: revenue n/a, net income −$13.4M, EPS -0.25
Recent QNCX insider trades
- Dec 26, 2025: Benatti Luca sold 50,000 shares ($174K)
5%+ owners
- GROUP ONE TRADING LLC: 10.7% (Schedule 13G, filed Mar 5, 2026)
- BALYASNY ASSET MANAGEMENT L.P.: 10.0% (Schedule 13G, filed Aug 14, 2026)
- Cormorant Asset Management, LP: 10.0% (Schedule 13G, filed Aug 14, 2026)
- Ikarian Capital, LLC: 9.0% (Schedule 13G, filed Aug 14, 2026)
- Perceptive Advisors LLC: 8.4% (Schedule 13G, filed Oct 14, 2026)
- Millennium Management LLC: 7.2% (Schedule 13G, filed Jun 10, 2026)
Are insiders buying or selling QNCX?
Over the last 12 months insiders bought $0 and sold $174K of Quince Therapeutics, Inc. stock on the open market (SEC Form 4).